US Towns Face Budget Crises Over Weight-Loss Drug Costs

Cities and towns across the United States are facing mounting budget pressure as the cost of covering popular weight-loss drugs for public employees surges [2]. These GLP-1 medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, have become a primary driver of rising healthcare expenses for local government health plans [2].

The financial strain is forcing some organizations to reconsider their coverage policies entirely. Cigna, for instance, announced it will stop covering these specific GLP-1 weight-loss drugs for its own employee health plan effective July 1 [2]. This shift comes as self-funded employers grapple with the broader issue of escalating medical costs, which are often exacerbated by high commercial pricing that can reach 282% of Medicare rates for equivalent services [2].

The fiscal impact on public entities is significant. In Texas, for example, there is ongoing debate regarding the solvency of the state’s teacher health program, TRS ActiveCare, with some observers questioning whether supplemental state funding is merely masking deeper financial instability [2]. While some officials in Austin maintain the program remains solvent, the tension highlights the difficulty of balancing comprehensive employee benefits against the reality of double-digit rate increases and the high cost of new medical treatments [2].

The challenge is further complicated by the structure of many public health plans. Many rely on traditional PPO networks, which critics argue often fail to control costs compared to alternative models like reference-based pricing [2]. As employers search for ways to manage these expenses, they face a complex landscape of billing errors, upcoded procedures, and the high cost of physician-administered medications that often go unmonitored by standard plan administrators [2].

While the federal government plans to introduce a limited Medicare GLP-1 demonstration project in 2026, the immediate burden remains on local municipalities to manage their own plan sustainability [2]. Whether these towns can continue to offer broad access to expensive new therapies without triggering unsustainable tax or budget hikes remains the central question for local administrators.